What Rybodyn does

Rybodyn, Inc. is a pre-clinical-stage biotechnology company developing first-in-class cancer immunotherapies that target disease-specific cryptic proteins sourced from the dark proteome—regions of the genome previously considered non-coding and undruggable. The company's core offering is the RyboCypher™ discovery engine, which integrates deep RNA sequencing of non-canonical transcripts with mass spectrometry-based proteomic detection and proprietary AI models to predict proteins that conventional sequencing methods overlook. These predictions are organized in CypherAtlas™, a searchable proprietary database covering approximately 1,000 patient tumor samples across 10 oncology indications, encompassing more than 3 million conserved novel dark RNAs, 80,000+ cryptic peptides (including ~15,000 cancer-specific peptides), and 117 validated Cryptic Targets™. One validated target is present in roughly 45% of HER2-negative breast cancer tumors analyzed, addressing a market estimated at $21 billion annually for non-HER2 breast cancer treatments. Rybodyn has demonstrated the first-ever in vitro ADC-mediated killing of tumor cells via a cryptic protein target.

The company translates these discoveries into a pipeline of antibody-based drug candidates—including antibodies, ADCs, and cell therapies—intended for oncology indications where conventional targets (e.g., HER2, EGFR, PD-1/PD-L1) are absent or saturated, with over 200 drugs already in development against EGFR alone. Rybodyn's commercial logic is asset-centric and partnership-driven: it advances programs internally toward IND-enabling studies while pursuing co-development, validation, and licensing arrangements with large pharmaceutical partners. The company has secured strategic footholds inside Eli Lilly's Gateway Labs at the One Alexandria Square Megacampus in Torrey Pines, a target-validation collaboration with Moffitt Cancer Center, an AI infrastructure alliance via NVIDIA Inception, and an inbound IP license from OHSU Knight Cancer Institute covering single-cell functional drug profiling and spatial biology methods. Revenue is not yet generated; the stated model is therapeutic development and licensing/royalties upon commercialization, with current capital deployment funded by a $4M pre-seed round (January 2025) and a $10M seed round (March 2026) from a syndicate that includes Genedant Capital, SeaX Ventures, SOSV, Swell VC, Massive Tech Ventures, and P2V.

Name

Rybodyn

Legal name

Rybodyn, Inc.

Website

https://rybodyn.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Rybodyn is a pre-clinical biotechnology company developing first-in-class cancer immunotherapies that target disease-specific cryptic proteins from the dark proteome, using its proprietary RyboCypher™ AI platform and CypherAtlas™ database to enable antibody and ADC drug candidates.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy / Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF)

Keywords

• Cancer immunotherapy
• Dark proteome targets
• Antibody drug discovery
• RNA sequencing platform
• Oncology therapeutics

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel

Revenue model

1. Therapeutic Development and Licensing: RyboDyn is developing a pipeline of antibody-based drug candidates targeting Cryptic Targets™ for cancer immunotherapy. The company plans to advance programs internally and through strategic partnerships with large pharmaceutical companies, with a focus on first-in-class immunotherapies for oncology.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

RyboDyn is a pre-clinical biotechnology company that uses its proprietary RyboCypher™ platform, which combines deep RNA sequencing with AI models trained on proprietary transcriptomic and proteomic databases, to discover disease-specific, druggable Cryptic Targets™ from the dark proteome. The company translates these targets into a pipeline of antibody-based drug candidates (including ADCs, antibodies, and cell therapies) for cancer immunotherapy, with an initial focus on HER2-negative and triple-negative breast cancer.

Product overview

RyboDyn is a biotechnology company that has developed an integrated platform for discovering and developing immunotherapies targeting the dark proteome. The core of the offering is the RyboCypher™ platform, which combines proprietary RNA sequencing with AI-driven analysis to identify previously hidden therapeutic targets from non-coding genomic regions. CypherAtlas™ serves as the proprietary database powering the platform, containing data from patient tumor samples across multiple oncology indications. The company translates these discoveries into Cryptic Targets™—novel, cancer-specific therapeutic targets—for development of first-in-class antibody-based immunotherapies.

Differentiator

Problem solved

Functional benefit

Products and services

• RyboCypher™ Discovery Platform Proprietary discovery engine that combines deep RNA sequencing of non-canonical RNAs with proteomic detection and AI models trained on proprietary databases to identify disease-specific, druggable targets from patient tumors. Internal R&D platform used by RyboDyn to turn the dark proteome into a portfolio of therapeutic targets.
• CypherAtlas™ Database Proprietary, searchable atlas integrating transcriptomic and proteomic data from approximately 1,000 patient tumor samples across 10 oncology indications. Contains over 3 million conserved novel dark RNAs, 80,000+ cryptic peptides (including ~15,000 cancer-specific peptides), and powers foundational AI models to decode the dark proteome at scale. Internal data asset supporting RyboDyn's discovery programs.
• Cryptic Targets™ Therapeutic Candidate Pipeline Pipeline of 117 validated Cryptic Targets—previously undiscovered, disease-specific, druggable targets representing unique chemical handles on the surface of cancer cells. These cryptic proteins are undetectable by conventional tools and form the foundation for antibody-based drug candidates (ADCs, antibodies, cell therapies) including a lead target present in ~45% of HER2-negative breast cancer tumors analyzed.

Quantifiable outcome

• Target present in ~45% of HER2-negative breast cancer tumors analyzed
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Partnerships

Four partnerships are on record, tiered major and core.

• NVIDIA (NVIDIA Inception)majorTechnology or Integration · 27 January 2026RyboDyn joined NVIDIA Inception program supporting continued expansion of AI systems powering CypherAtlas™. Provides access to advanced computing infrastructure and global ecosystem of AI-native companies to accelerate data generation and model development.
• Eli Lilly and Company (Lilly Gateway Labs)coreStrategic or Co-development Partner · 19 June 2025RyboDyn selected to join Lilly Gateway Labs in San Diego, providing direct access to Eli Lilly's global scientific and business network. Part of Lilly Catalyze360™ model at One Alexandria Square Megacampus in Torrey Pines. Enables access to world-class lab space, drug development talent, and resources.
• Moffitt Cancer CentercoreStrategic or Co-development Partner · 15 May 2025Strategic collaboration to validate Cryptic Targets™ across a wide array of tumor types using Moffitt's uniquely annotated tumor repository—one of the largest in the world. Dr. Alex Jaeger from Moffitt independently confirmed RyboDyn's discovery on cell surfaces. Collaboration confirmed targets are conserved across patients and absent in healthy tissues.
• Oregon Health & Science University (OHSU) Knight Cancer InstitutecoreStrategic or Co-development Partner · 17 June 2024Original discovery of cryptic human proteome made by Dr. Dambacher and Co-founder Ashley Woodfin while at OHSU. Company licensed patent rights to three OHSU technologies including single-cell functional drug profiling and spatial biology applications.

Scale indicators7 records

Emerging players

• Genesis Therapeutics: AI-driven drug discovery platform combining molecular simulation and foundation models to identify novel small molecules and biologics. Comparable as a venture-backed AI biotech pursuing novel therapeutic targets.
• Cradle Bio: AI platform for protein engineering and biologics design. Comparable through shared AI/biology intersection and therapeutic protein focus, though Cradle emphasizes engineering existing proteins rather than discovering cryptic ones.
• Isomorphic Labs: Alphabet-backed AI drug discovery company leveraging AlphaFold-related protein structure prediction. Comparable as an AI-first protein/drug discovery platform with significant capital and computational resources.

Broad incumbents

• Moderna: Large commercial-stage biotech with growing oncology and immunotherapy pipeline. Comparable as a platform biotechnology company expanding beyond its original modality into cancer therapeutics.
• BioNTech: Established cancer immunotherapy leader with broad pipeline of antibody, mRNA, and cell therapy candidates. Comparable as a deep-pipeline oncology immunotherapy company, though at vastly larger scale and with broader therapeutic modalities.

Direct peers

• Insitro: Machine learning-driven drug discovery platform combining proprietary data generation with predictive models to accelerate therapeutic development. Comparable as an AI/omics-platform biotech, with overlap in target identification workflows.
• AbCellera Biologics: AI-powered antibody discovery platform with a proprietary data and wet-lab stack. Directly comparable to Rybodyn as a platform company turning proprietary data into antibody therapeutic candidates, though AbCellera focuses on conventional antigen targets rather than the dark proteome.
• Recursion Pharmaceuticals: Tech-enabled biopharma using high-throughput biology and AI to discover novel therapeutic targets at scale. Comparable as a platform company leveraging proprietary data and AI to identify previously unexplored disease biology.
• Generate Biomedicines: AI-driven generative biology platform designing novel protein therapeutics from scratch. Highly comparable to Rybodyn's AI-driven protein prediction approach and focus on creating previously non-existent therapeutic candidates.
• Absci: AI-first drug creation company combining generative AI with a wet-lab platform to design and validate novel antibody therapeutics. Comparable as an AI-native antibody discovery platform, though focused on de novo design rather than cryptic antigen identification.

Market position

Strengths5 records

Weaknesses5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/rybodyn

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rybodyn